4170.TWO Vectorite Biomedical Inc.

Healthcare Biotechnology Taiwan OTC Exchange
11.00 TWD
Close of Nov 6, 2026
10.50 18.15
Market cap
TWD 481M
P/E
4.1x
P/B
0.98x
ROE
19.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 4170.TWO undervalued?

Graham number
Price11.00
Graham value26.10
Discount57.9%

4170.TWO trades 57.9% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Vectorite Biomedical Inc. fundamental analysis

No fundamental analysis for Vectorite Biomedical Inc. yet.

Vectorite Biomedical Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Vectorite Biomedical Inc.

Vectorite Biomedical Inc. engages in the research and development of biotechnology in Taiwan and internationally. The company is involved in cell preparation product manufacturing; and collection and storage of immune cells. Its products are used in the field of infectious diseases and inflammation, cancer, and oncology. The company was incorporated in 2004 and is based in New Taipei City, Taiwan.

Full company profile